Home Current Events GameStop: Why It’s Possible for Stocks to Be Sold Short
GameStop: Why It’s Possible for Stocks to Be Sold Short

GameStop: Why It’s Possible for Stocks to Be Sold Short

0

Guest Post by Dr. Michael Driscoll

I connected with a friend, Dr. Michael Driscoll, to discuss the GameStop situation, specifically as it relates to selling a stock short. Dr. Driscoll is the former dean of the Richard J. Bolte, Sr. School of Business at Mt. St. Mary’s University.

Prior to joining the academy, he was a trader at a hedge fund and worked in a variety of trading roles for a number of investment banks. Before he began his career in investment banking, he was a Merchant Marine officer. I might note that he has a decent golf game as well. Here are a few of his thoughts.

Like most people who have even a passing interest in the financial markets, I have been following the story of Robinhood/Reddit investors and their attempts to battle the short sellers — primarily hedge funds — in stocks like GameStop (ticker symbol GME), AMC Entertainment (AMC), Blackberry (BB), and others. I suspect that as a former business school dean and a 28-year Wall Streeter, my perspective is a little different than many of my academic peers.

I have little interest in debating the advantages of the democratization of the investment process or the relative merits of the Efficient Market Hypothesis. However, I think I can make some of this situation easier to understand.

Let’s start with why an investor, individual or institutional, might consider selling a stock short. An investor performs all their research and due diligence on a company and can essentially do one of three things: buy, sell, or hold (do nothing).

If someone had analyzed GME and felt that the stock was undervalued and that the company’s fortunes were going to improve due to the pandemic easing or new people joining the board, they could purchase shares. If someone does the same analysis and concludes that the pandemic is going to last longer than expected or that GME is going to go the way of Blockbuster Video and declare bankruptcy at some point, they can borrow shares from an existing holder.

This process is handled by the “stock loan” department of brokerage firms. This department “locates” shares for the short seller, and they are sold in the market. The hope is that these shares may be bought back or “covered” at some point in the future at a lower price than what they were sold for. If the decision is to hold, obviously no action is taken.

All short sales have to be identified as such. There is a published indicator called a stock’s “short interest,” which is basically how many shares of a company have been shorted. Not every share sold short is necessarily a bet on the stock declining.

But this is where the story gets interesting. Some entities are acting as “market makers” for derivatives such as listed options contracts, futures, or convertible bonds. A portion of this short interest can be neutral positions that these market makers have utilized to hedge positions.

Since 1973 when the Chicago Board Options Exchange (CBOE) began trading listed options on just 11 stocks, the world of finance has never been the same. Options give a purchaser the right — but not the obligation — to buy (calls) or to sell (puts), which are usually 100 shares of the underlying security.

In the interest of simplicity, let’s consider GME. All of these numbers are theoretical, but I think you will get the gist of the example.

Let’s say GME was trading at $20, and someone has the opinion that the stock can go to $30. If they purchase 100 shares of GME and it goes up 10 points, they make a nice 50% return.

Someone could buy a GME call option that expires in one month with a strike price of $25 that would grant the purchaser the right, but not the obligation, to purchase the stock for $25 for one month. To get this right, they might pay $2 per share ($2 x 100 shares or $200 in total).

Now if the stock stays below $25, the option would expire at the end of a month and the purchaser would lose his $200 investment. For this reason, listed options are referred to as a “wasting asset.”

If the stock went to $30, the option would now have an “intrinsic value” of $5 (stock price of $30 minus the strike price of $25 = $5). This “leverage” of buying for $2 and selling for $5, a 150% return, is a major attraction for option purchasers.

Now, let’s think about these two strategies for a second. Who is the seller of that call option? If there is a buyer, there must be a seller.

One variety of seller is the professional trader or market maker. They will sell, or write, a call in options parlance, for the $2 premium. They can stay unhedged or “naked,” but if the stock rises, they would face increasing losses. They will usually buy shares to protect their position.

Let’s say 30 shares out of the 100 that they may have at risk are initially at the strike price of $25. As the stock rises, these market makers are forced to buy more shares to protect their positions. A stock that rises as fast and as far as a GME stock has in the last few weeks exacerbates this scramble to cover short positions by options market makers.

Add those hedge funds who may have been short the stock initially betting on GME’s demise, and the frenzy of the last weeks makes more sense. This “pain trade” of bearish short sellers being forced to cover their positions is a factor that the financial press has emphasized, but I suspect the squeeze was just as painful for options traders.

There is much more to this situation than the example that I used, but I tried to keep the example as simple as possible. What I would like to emphasize is that not every short sale is necessarily a negative bet on the price of a stock.

Comments

comments

Wally Boston Dr. Wallace E. Boston was appointed President and Chief Executive Officer of American Public University System (APUS) and its parent company, American Public Education, Inc. (APEI) in July 2004. He joined APUS as its Executive Vice President and Chief Financial Officer in 2002. In September 2019, Dr. Boston retired as CEO of APEI and retired as APUS President in August 2020. Dr. Boston guided APUS through its successful initial accreditation with the Higher Learning Commission of the North Central Association in 2006 and ten-year reaccreditation in 2011. In November 2007, he led APEI to an initial public offering on the NASDAQ Exchange. For four years from 2009 through 2012, APEI was ranked in Forbes' Top 10 list of America's Best Small Public Companies. During his tenure as president, APUS grew to over 85,000 students, 200 degree and certificate programs, and approximately 100,000 alumni. While serving as APEI CEO and APUS President, Dr. Boston was a board member of APEI, APUS, Hondros College of Nursing, and Fidelis, Inc. Dr. Boston continues to serve as a member of the Board of Advisors of the National Institute for Learning Outcomes Assessment (NILOA), a member of the Board of Overseers of the University of Pennsylvania’s Graduate School of Education, and as a member of the board of New Horizons Worldwide. He has authored and co-authored papers on the topic of online post-secondary student retention, and is a frequent speaker on the impact of technology on higher education. Dr. Boston is a past Treasurer of the Board of Trustees of the McDonogh School, a private K-12 school in Baltimore. In his career prior to APEI and APUS, Dr. Boston served as either CFO, COO, or CEO of Meridian Healthcare, Manor Healthcare, Neighborcare Pharmacies, and Sun Healthcare Group. Dr. Boston is a Certified Public Accountant, Certified Management Accountant, and Chartered Global Management Accountant. He earned an A.B. degree in History from Duke University, an MBA in Marketing and Accounting from Tulane University’s Freeman School of Business Administration, and a Doctorate in Higher Education Management from the University of Pennsylvania’s Graduate School of Education. In 2008, the Board of Trustees of APUS awarded him a Doctorate in Business Administration, honoris causa, and, in April 2017, also bestowed him with the title President Emeritus. In August 2020, the Board of Trustees of APUS appointed him Trustee Emeritus. In November 2020, the Board of Trustees announced that the APUS School of Business would be renamed the Dr. Wallace E Boston School of Business in recognition of Dr. Boston's service to the university. Dr. Boston lives with his family in Austin, Texas.

LEAVE YOUR COMMENT

Your email address will not be published. Required fields are marked *